Agilent Expands FDA-Approved PD-L1 Testing for KEYTRUDA Across Four Cancer Types
SANTA CLARA, Calif., June 2, 2026 Agilent Technologies announced that the U.S. Food and Drug Administration (FDA) has approved...
Agilent Technologies
Advertisement
Iterion Reports First Clinical Validation of Tegavivint in Advanced HCC
HOUSTON, June 1, 2026 Iterion Therapeutics has unveiled compelling clinical data supporting tegavivint, its first-in-class Wnt/β-catenin pathway inhibitor, as...
Agilent and Sound Analytics Advance Drug Metabolism LC/MS
SANTA CLARA, Calif., June 1, 2026 Agilent Technologies and Sound Analytics have announced a strategic collaboration aimed at transforming...
Agilent Wins FDA Approval for PD-L1 22C3 Test
Santa Clara, USA – March 26, 2026 Agilent Technologies announced U.S. FDA approval of its PD-L1 IHC 22C3 pharmDx...
Advertisement
